Original article

Incidence and mortality analysis of biliary tract cancer in Shanghai: population-based study from 2002 to 2020

  • WU Chunxiao ,
  • PANG Yi ,
  • CHEN Lei ,
  • SHI Yan ,
  • GU Kai
Expand
  • Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201107, China

Received date: 2025-05-05

  Online published: 2025-09-01

Abstract

Objective To analyze the epidemiological characteristics and trends of the incidence and mortality of biliary tract cancer in Shanghai from 2002 to 2020. Methods Data on new cases and deaths of malignant tumors of the gallbladder, extrahepatic bile ducts, and other biliary tract organs from 2002 to 2020 were obtained from the Population-based Cancer Registry and Vital Statistics System of Shanghai Municipal Center for Disease Control and Prevention. Cases or deaths, proportion, crude rate, age-specific rate, age-standardized rate (ASR) and others were calculated stratified by year of diagnosis or death, gender and age-group. ASRs were calculated using Segi′s 1960 world standard population. Trends of the annual percent change (APC) of ASRs, age-specific rates and proportions of new cases with selected diagnostic character of biliary tract cancer stratified by different groups were analyzed by Joinpoint analysis software. Results Annual new cases of biliary tract cancer in Shanghai increased from 963 in 2002 to 1 537 in 2020, with ASR of incidence changing from 3.91/10⁵ to 3.59/10⁵. Annual deaths increased from 830 to 1 225, with ASR of mortality decreased from 3.36/10⁵ to 2.69/10⁵. In 2020, the crude rate of incidence of biliary tract cancer was 10.43/10⁵ (9.54/10⁵ in males and 11.30/10⁵ in females) in Shanghai, and the ASR was 3.59/10⁵ (3.54/10⁵ in males and 3.61/10⁵ in females), with no statistically significant gender difference (P=0.731). The crude rate of mortality was 8.31/10⁵ (7.60/10⁵ in males and 9.00/10⁵ in females), and the ASR was 2.69/10⁵ (2.69/10⁵ in males and 2.66/10⁵ in females), also with no significant gender difference (P=0.874). Age-specific nunbers and rates of incidence and mortality generally increased with aging. Stratified by gender, the trend of ASRs of incidence of biliary tract cancer in Shanghai in males showed no significant change (P=0.179) from 2002 to 2020, nor did that of ASRs of mortality (P=0.738). In females, the ASRs of incidence decreased at an average annual rate of 1.58% (P<0.001), while the trend of ASRs of mortality showed no significant change from 2002 to 2011 (P=0.774), but ASRs decreased at an average annual rate of 3.72% from 2011 to 2020 (P<0.001). Among new cases, the proportions of morphological verification increased, while the proportions of imaging verification decreased. The gallbladder was the most common site, but its proportions decreased significantly, whereas the proportions of extrahepatic bile duct increased from 25.75% to 42.88%. Over 60% of cases were unknown stage at diagnosis, while the combined proportions of stages Ⅰ-Ⅲ remained less than that of stage Ⅳ. Conclusions The ASRs for incidence and mortality of biliary tract cancer in Shanghai remain relatively high, with distinct epidemiological characteristics. The improvement in the diagnosis and treatment of biliary diseases maybe have impact on the incidence patterns of biliary tract cancer in Shanghai, but the effect on increasing survival rates and reducing mortality rates is relatively lagging. It needs a big progress to advance the screening, diagnosis, and survival of biliary tract cancer in Shanghai. This study provides a foundation for further research and prevention strategies for biliary tract cancer.

Cite this article

WU Chunxiao , PANG Yi , CHEN Lei , SHI Yan , GU Kai . Incidence and mortality analysis of biliary tract cancer in Shanghai: population-based study from 2002 to 2020[J]. Journal of Surgery Concepts & Practice, 2025 , 30(03) : 214 -222 . DOI: 10.16139/j.1007-9610.2025.03.06

References

[1] WHO Classification of Tumours Editorial Board. Digestive system tumours[M]// World Health Organization classification of tumours, 5th ed. Geneva: WHO Press, 2024.
[2] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[3] 顾凯, 庞怡, 吴春晓, 等. 2017年上海市恶性肿瘤发病和死亡情况与2002—2017年的变化趋势分析[J]. 肿瘤, 2023, 43(4):241-256.
  GU K, PANG Y, WU C X, et al. Analysis of the current status of cancer incidence and mortality in Shanghai, 2017 and trends of 2002-2017[J]. Tumor, 2023, 43(4):241-256.
[4] 国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京: 人民卫生出版社,2016:59-75.
  National Cancer Center. Chinese guideline for cancer re-gistration(2016)[M]. Beijing: People's Medical Publishing House,2016:59-75.
[5] PARKIN D M, CHEN V W, FERLAY J, et al. Comparability and quality control in cancer registration. IARC Technical Report No.19[M]. Lyon: IARC Press,1994.
[6] 上海市疾病预防控制中心. 上海市恶性肿瘤发病率、死亡率和生存率(2001—2012)[M]. 上海: 上海科学普及出版社,2017:1-6.
  Shanghai Municipal Center for Disease Control & Prevention. Cancer incidence, mortality and survival rates in Shanghai(2001—2012)[M]. Shanghai: Shanghai General Science Press,2017:1-6.
[7] 卢伟, 郑莹. 肿瘤命名与编码[M]. 上海: 第二军医大学出版社, 2011.
  LU W, ZHENG Y. Tumor nomenclature and coding[M]. Shanghai: Second Military Medical University Press, 2011.
[8] SEGI M. Cancer mortality for selected sites in 24 countries (1950—1957)[M]. Sendai: Tohoku University School of Medicine,1960.
[9] Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 4.8.0.1[CP]. Bethesda,Maryland: National Cancer Institute, 2020.
[10] KIM H J, FAY M P, FEUER E J, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Stat Med, 2000, 19(3):335-351.
[11] ESTèVE J, BENHAMOU E, RAYMOND L. Statistical methods in cancer research. Volume Ⅳ. Descriptive epidemiology[J]. IARC Sci Publ, 1994,(128):1-302.
[12] HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[13] 国家癌症中心. 2022中国肿瘤登记年报[M]. 北京: 人民卫生出版社,2025:148-151.
  National Cancer Center. 2022 Chinese cancer registry annual report[M]. Beijing: People′s Medical Publishing House,2025:148-151.
[14] P BRAY F, COLOMBET M, AITKEN JF, et al. Cancer incidence in five continents Vol. Ⅻ. IARC Scientific Publications No.169[M]. Lyon: International Agency for Research on Cancer, 2024.
[15] 杨晓静, 王家冉, 靳婷, 等. 2000—2021年浙江省肿瘤登记地区胆囊癌的流行现状与趋势分析[J]. 中国普外基础与临床杂志, 2025, 32(6):714-721.
  YANG X J, WANG J R, JIN T, et al. Analysis of the prevalence status and trend of gallbladder cancer in Zhejiang Province from 2000 to 2021[J]. Chin J Bases Clin Gen Surg, 2025, 32(6):714-721.
[16] 沈欢, 孙中明, 缪丹丹, 等. 2009—2019年江苏省肿瘤登记地区胆囊癌发病趋势及年龄变化分析[J]. 中国肿瘤外科杂志, 2024, 16(3):215-220.
  SHEN H, SUN Z M, MIAO D D, et al. Analysis on the trends of gallbladder cancer incidence and age change in cancer registration regions of Jiangsu Province,2009 to 2019[J]. Chin J Surg Oncol, 2024, 16(3):215-220.
[17] LEWIS S J, HEATON K W, OAKEY R E, et al. Lower serum oestrogen concentrations associated with faster intestinal transit[J]. Br J Cancer, 1997, 76(3):395-400.
[18] 吴春晓, 鲍萍萍, 黄哲宙, 等. 上海市消化系统常见恶性肿瘤发病现况和时间趋势分析[J]. 胃肠病学, 2012, 17(9):513-520.
  WU C X, BAO P P, HUANG Z Z, et al. Current prevalence of common digestive system cancer in Shanghai and analysis of its trends[J]. Chin J Gastroenterol, 2012, 17(9):513-520.
[19] CHAN T F, WU C H, CHIU H F, et al. Parity and risk of death from gallbladder cancer among a cohort of premenopausal parous women in Taiwan[J]. Int J Environ Res Public Health, 2015, 12(2):1864-1873.
[20] EKBOM A, HSIEH C C, YUEN J, et al. Risk of extrahepatic bileduct cancer after cholecystectomy[J]. Lancet, 1993, 342(8882):1262-1265.
[21] HSING A W, GAO Y T, HAN T Q, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China[J]. Br J Cancer, 2007, 97(11):1577-1582.
[22] NOGUEIRA L, FREEDMAN N D, ENGELS E A, et al. Gallstones, cholecystectomy, and risk of digestive system cancers[J]. Am J Epidemiol, 2014, 179(6):731-739.
[23] 吴春晓, 顾凯, 庞怡, 等. 2002—2013年上海市恶性肿瘤生存分析[J]. 肿瘤, 2023, 43(4):257-265.
  WU C X, GU K, PANG Y, et al. Survival analysis of cancer cases diagnosed during 2002—2013 in Shanghai: a population-based study[J]. Tumor, 2023, 43(4):257-265.
[24] HENLEY S J, WEIR H K, JIM M A, et al. Gallbladder cancer incidence and mortality, United States 1999-2011[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(9):1319-1326.
[25] 郑杨, 王春芳, 吴春晓, 等. 《“健康上海2030”规划纲要》三项主要指标解读[J]. 上海预防医学, 2018, 30(1):11-14.
  ZHENG Y, WANG C F, WU C X, et al. Interpretation of three main indicators of the “2030 Plan for Healthy Shanghai”[J]. Shanghai J Prev Med, 2018, 30(1):11-14.
Outlines

/